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Abstract 
Kainic acid (KA) causes seizures and neuronal loss in the hippocampus. The present 
study investigated whether a recreational schedule of 3,4-
methylenedioxymethamphetamine (MDMA) favours the development of a seizure state 
in a model of KA-induced epilepsy and potentiates the toxicity profile of KA (20 or 30 
mg/kg). Adolescent male C57BL/6 mice received saline or MDMA t.i.d. (s.c. every 3 
h), on 1 day a week, for 4 consecutive weeks. Twenty-four hours after the last MDMA 
exposure, animals were injected with saline or KA (20 or 30 mg/kg). After this 
injection, we evaluated seizures, hippocampal neuronal cell death, microgliosis, 
astrogliosis, and calcium binding proteins. MDMA pretreatment, by itself, does not 
induce neuronal damage but increases seizure susceptibility in all KA treatments and 
potentiates the presence of Fluoro-Jade-positive cells in CA1. Furthermore, MDMA, 
like KA, significantly decreased parvalbumin levels in CA1 and dentate gyrus, where it 
potentiated the effects of KA. The amphetamine also promoted a transient decrease in 
calbindin and calretinin levels, indicative of an abnormal neuronal discharge. In 
addition, treatment of cortical neurons with MDMA (10-50 µM) for 6 or 48 h 
significantly increased basal Ca2+ levels and potentiated Ca2+ influx after NMDA 
challenge. In parallel, basal Na+ levels were reduced and kainate response were 
increased after pre-incubation with MDMA. These results indicate that MDMA 
potentiates KA-induced neurodegeneration and also increases KA seizure susceptibility. 
The mechanism proposed includes changes in Calcium Binding Proteins expression, 
probably due to the disruption of intracellular (calcium) ionic homeostasis, or/and an 
indirect effect through glutamate release. 
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Introduction  
A substantial number of studies have been performed on the neuropharmacological 
mechanisms involved in the adverse effects of 3,4-methylenedioxymethamphetamine 
(MDMA, “Ecstasy”) in laboratory animals, in which it has been shown to be neurotoxic 
to dopamine (DA) and serotonin (5-HT) terminals. It is well known that these 
neurotoxic effects are species-dependent (Logan et al., 1988). In mice, it is generally 
agreed that MDMA, at high doses, induces a dopaminergic terminal injury in the 
striatum (Chipana et al., 2006) and disrupts 5-HT neurochemistry in the hippocampus, 
depending on schedule dose used.  In contrast, administration of a neurotoxic regimen 
of this amphetamine derivative to rats results in a selective reduction in cerebral tissue 
concentrations of 5-HT and also in 5-HT uptake sites in cortex and hippocampus, 
pointing to a selective injury of serotonergic terminals (Green et al., 2003; Pubill et al., 
2003). 
Likewise recent reports documented the finding that repeated exposure of rats to 
MDMA increases glutamate release in the hippocampus (Anneken and Gudelsky, 
2012). Sustained increases in extracellular glutamate have the potential to promote 
excitotoxicity and could be involved in the neurotoxic effects of MDMA in the brain 
(Capela et al., 2006).  
Collectively all these data provide support to the suggestion that the consequences of 
chronic exposure to MDMA are not only limited to specific terminal neurons, but that 
other elements are also susceptible to damage. In this sense, changes in the EEG records 
have been described in long-term MDMA users and epileptic seizures associated with 
these altered records are one of the most frequent disturbances in ecstasy abusers 
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(Zagnoni and Albano, 2002). Giorgi et al. (Giorgi et al., 2005) reported, for the first 
time, that MDMA lowered the threshold for kainate-induced seizures.  These data are 
important because MDMA might predispose to seizures due to alterations in brain 
excitability (Zagnoni and Albano, 2002; Brown et al., 2011) or increasing basal calcium 
levels (Garcia-Ratés et al., 2010). However there have been few studies evaluating the 
proconvulsant effect of MDMA in experimental models of epilepsy (Giorgi et al., 2005) 
and they use a different schedule of MDMA administration than that of the present 
study. 
Kainic acid (KA) has been widely used for its ability to replicate many of the 
phenomenological features of human temporal lobe epilepsy (Ben-Ari and Cossart, 
2000; Leite et al., 2002). Seizures cause extensive brain damage concomitant with an 
increase in reactivity of the glia, as well as failure of the cellular homeostasis (Niquet et 
al., 1994; Represa et al., 1995; Cavazos et al., 2004; Kondratyev and Gale, 2004; 
Junyent et al., 2011). KA has direct excitatory effects on neurons but its potent 
neurotoxic action involves also the activation of presynaptic receptors on glutamatergic 
terminals, thereby releasing Asp and Glu. Endogenous glutamate, by activating NMDA, 
AMPA or mGluR1 receptors, may contribute to the brain damage occurring acutely 
after status epilepticus (Meldrum, 2000). 
The aim of the present study was to evaluate whether the MDMA favours the 
development of a seizure state in adolescent mice treated with the neurotoxin KA. We 
used a regimen of MDMA that differed from the classic neurotoxic exposure, trying to 
simulate classical adolescent weekend binge use of this substance. We observed a 
decrease in time to first seizure and an increase in seizure activity induced by KA. We 
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also investigated whether hippocampal neurotoxicity after two different doses of KA is 
potentiated by MDMA.  
Calcium binding proteins (CaBP) are expressed by distinct subsets of GABAergic 
interneurons in the hippocampus and they are crucial for calcium homeostasis in 
neurons. These include parvalbumin (PV), calbindin-D28k (CB) and calretinin (CR). 
These proteins afford neuroprotection by preventing the sustained increase of 
intracellular calcium. In the present study, using immunohistochemistry for PV, CB and 
CR, we compared the KA-associated changes in hippocampal regions with those 
induced by MDMA or their combination. Analysis of these markers could provide data 
to indicate whether one, two, or all of the GABAergic interneuron subtypes might be 
abnormal in the hippocampus of animals exposed to the above-mentioned substances. 
Based on the MDMA effects described by Anneken and Gudelsky (Anneken and 
Gudelsky, 2012), we have limited the study to the hippocampus. Because the entry of 
calcium into neurons is strongly associated with seizures (Meyer, 1989; McNamara, 
1992), we also carried out in vitro experiments in cortical neuron cultures to corroborate 
the effects of MDMA on calcium homeostasis. Our data indicate that MDMA 
potentiates KA-induced neurodegeneration and also increases KA seizure susceptibility.  
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Experimental Procedures 
Animals 
Adolescent male C57/BL6 mice (4-5 weeks old) (Charles River Laboratories, France) 
were kept under controlled temperature, humidity and light conditions with food and 
water provided ad libitum. They were treated according to European Community 
Council Directive 86/609EEC and the procedure registered at the Department 
d’Agricultura, Ramaderia i Pesca of the Generalitat de Catalunya. Efforts were made to 
minimize animal suffering and to reduce the number of animals used. 
Drug treatments and sample preparation 
To model recreational MDMA use, we used adolescent mice. It could also be 
considered appropriate to simulate the widespread practice of “stacking” (taking 
multiple doses at once in order to increase the desired effect and/or overcome tolerance 
from prior use) and “boosting” (taking supplemental doses over time in order to 
maintain the drug’s effect) (Hammersley et al., 1999; Meyer et al., 2008). To select the 
appropriate MDMA dose we took into account that the dose regimen used in neurotoxic 
experiments with mice is 25 mg/kg three times per day (tid) every 3h (Colado et al., 
2001) or 20 mg/kg every 2h for a total of four injections (O’Callaghan and Miller, 
1994). Consequently, a maximal dose of 10 mg/kg tid was choosen. Treatment schedule 
started with a standard psychostimulant dose of MDMA (5 mg/kg) (Spanos and 
Yamamoto, 1989) that increased over the treatment, imitating the classic consumption 
of a reinforcing compound. In order to simulate its recreational use, MDMA was 
administered  once a week during all the adolescent period (from week 4 to week 8 of 
age) (Smith, 2003). Drug administration was carried out at high environmental 
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temperature, thus simulating the hot environments in which this substance tends to be 
consumed (clubs, raves).  
Initially, animals were randomly assigned to the following treatment groups: 
saline+saline, MDMA+saline (M), saline+Kainate 20 mg/kg (KA20), MDMA+Kainate 
20 mg/kg (M+KA20), saline+Kainate 30 mg/kg (KA30), MDMA+Kainate 30 mg/kg 
(M+KA30).  
The animals (n=7-10) for every treatment group in each experiment received a chronic 
dosage regimen of saline (5 ml/kg) or MDMA t.i.d. (s.c, every 3 h) on 1 day a week (the 
same day every week), for 4 consecutive weeks. MDMA and KA doses and the 
treatment schedule were as illustrated in Figure 1. On the day of treatment, the 
environmental temperature was maintained at 26 ± 1°C until 2 h after the last dose. 
Thereafter, the animals were returned to normal housing conditions (22 ± 1°C). One 
hour after the second daily dose of saline or MDMA, rectal temperature was measured 
using a lubricated, flexible rectal probe inserted into the rectum and attached to a digital 
thermometer (0331 Panlab SL, Barcelona, Spain). The dose of MDMA increased every 
week. Accordingly the doses were: 5 mg/kg, 7.5 mg/kg (for 2 consecutive weeks) and 
10 mg/kg. Twenty-four hours after the last dose of MDMA or saline, animals were 
exposed to low/moderate (20 mg/kg) or high (30 mg/kg) epileptogenic KA i.p. doses 
(Santos and Schauwecker, 2003; Sonn et al., 2010).  
After the KA injection, the animals were put in individual plexiglas cages and observed 
for a period of 4 h to evaluate the occurrence and intensity of seizures. Seizures were 
assessed according to an adaptation of the Racine’s scale (Racine, 1972) consisting of 
seven stages (0–6), which correspond to the successive developmental stages of motor 
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seizures: (0) normal non-epileptic activity; (1) Still and crouched in a corner, staring; (2) 
Stretches body out, tail becomes straight and rigid, ears laid back, bulging eyes; (3) 
Repetitive head bobbing, rears into a sitting position with forepaws resting on belly (4) 
Rearing and falling tonic clonic seizures broken by periods of total stillness, jumping 
clonus, running clonus; (5) Continuous Level 4 seizures and (6) Body in clonus, no 
longer using limbs to maintain posture, usually precursor to death. 
The animals were killed 24 h or 72 h later. All mice were anaesthetized by i.p. injection 
of ketamine (100 mg/kg) and xylazine (10 mg/kg) and were perfused with 
paraformaldehyde 4% in phosphate buffer 0.1 M, after which the brains were removed. 
These were subsequently rinsed in paraformaldehyde 4% with 30% sucrose for 24 h and 
then frozen. Coronal sections of 30 μm were obtained. Brains from mice killed after 24 
h of KA treatment were used for microgliosis immunohistochemistry, and brains from 
mice killed after 3 days of KA treatment were used for GFAP immunohistochemistry. 
Fluoro-Jade B staining, calbindin-D28k, calretinin and parvalbumin 
immunohistochemistry were performed either at 24 or 72 h.  
Fluoro-Jade B staining 
Slides were defatted by dehydration in ethanol before being rehydrated, rinsed in 
phosphate-buffered saline (PBS), and incubated with 5 nmol/l of Hoechst 33342 for 10 
min in the dark. After two washes in distilled water, the slides were immersed in 0.06 
g/l of potassium permanganate (KmnO4) for 15 min in the dark. After two washes, the 
slides were transferred to the staining solution containing 0.1 ml/l of acetic acid and 4 
µl/l Fluoro-Jade B for 30 min, in the dark. Slides were rinsed in distilled water, dried, 
and then submerged directly in xylene and mounted in DPX medium. Slides were 
analysed with an epifluorescence microscope (Olympus BX61). 
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Immunohistochemistry 
Free-floating coronal sections were rinsed in 0.1 mol/l PB, pH 7.2, and then treated with 
5 ml/l H2O2 and 100 ml/l methanol in PBS for 15 minutes. After that, they were 
preincubated in a blocking solution (10% fetal bovine serum (FBS), 0.2 mol/l of 
glycine, Triton X-100 0.2% in 0.2% PBS-gelatin). Then, sections were incubated 
overnight at 4°C with different primary antibodies: rabbit anticalbindin-D28k, rabbit 
anticalretinin and rabbit antiparvalbumin (1:1,000; Swant, Belinzona, Switzerland), 
rabbit antiIba-1 (Wako Chemicals, Japan 1:1000) and rabbit antiglial fibrillary acidic 
protein (GFAP; 1:1,000; Dako, Denmark). After that, sections were incubated with 
biotinylated secondary antibodies (1:200; Sigma-Aldrich) for 2 h at room temperature 
and then incubated with the avidin-biotin-peroxidase complex (ABC; 1:200; Vector, 
Burlingame, CA). The peroxidase reaction was developed with 0.5 g/l 
diaminobenzidine in 0.1 mol/l PB and 0.1 ml/l H2O2, and immunoreacted sections were 
mounted on gelatinized slides. Stained sections were examined under a light microscope 
(Olympus BX61). 
Since the shape and marking profile of PV-positive cells was well defined and they 
were not very numerous, they were counted manually by and experimenter blinded to 
the experimental conditions. Cell counts were carried out with Photoshop 5.0 software 
after acquiring digitized images with the microscope (Olympus BX61, 25×objective) 
equipped with a digital camera. GFAP, calbindin and calretinin immunostaining density 
in brain sections were determined using the ImageJ software (National Institute of 
Health), via which the regions of interest were defined and the corresponding intensity 
calculated. 
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Quantification of dopaminergic and serotonergic terminals 
Tissue sample preparation 
For dopamine and serotonin transporter quantification, the fresh brains of animals killed 
96 h post MDMA administration were used. Crude membrane preparations from the 
hippocampus and striatum were prepared as described elsewhere (Escubedo et al., 
2005). Samples were homogenized at 4°C in 20 volumes of buffer consisting of 5 mM 
Tris-HCl, 320 mM sucrose, and protease inhibitors (aprotinin 4.5 µg/µl, 0.1 mM 
phenylmethylsulfonyl fluoride, and 1 mM sodium orthovanadate), pH 7.4. The 
homogenates were centrifuged at 15,000 x g for 30 min at 4°C. The pellets were 
resuspended and centrifuged at 15,000 x g for 30 min at 4°C two more times. The final 
pellets (crude membrane preparation) were resuspended in the appropriate buffer and 
stored at -80°C until use in radioligand binding experiments. Protein content was 
determined using the Bio-Rad Protein Reagent, according to the manufacturer’s 
instructions. 
DA and 5-HT transporter density 
The density of DA transporter in mice striatal membranes was measured using 
[3H]WIN35428 binding assays. Membranes were resuspended in phosphate-buffered 
0.32 M sucrose, pH 7.9 at 4°C to a concentration of 1 µg/µl. Striatal  membrane assays 
were performed in glass tubes containing 250 µl of [3H]WIN 35428 (final radioligand 
concentration, 5 nM) and 50 µg of membranes. The tubes were incubated for 2 h at 4°C 
and non-specific binding was determined in the presence of 30 µM bupropion. 
The density of 5-HT transporter in the hippocampal membranes was quantified by 
measuring the specific binding of 0.05 nM [3H]paroxetine after incubation with 150 µg 
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of protein at 25ºC for 2 h in a Tris-HCl buffer (50 mM, pH 7.4), containing 120 mM 
NaCl and 5 mM KCl to a final volume of 1.6 ml. Clomipramine (100 µM) was used to 
determine non-specific binding. 
All incubations were finished by rapid filtration under vacuum though GF-51 glass fibre 
filters (Schleicher and Schuell, Dassel, Germany).  The radioactivity in the filters was 
measured by liquid scintillation spectrometry. 
Neuronal cell cultures  
Primary neuronal cultures of cerebral cortex were obtained from mice embryos (E-16-
18) as described by Crespo-Biel et al. [24] with minor modifications adapted to cortical
cells. Cell viability was assessed using two different methods, calcein and MTT, 
because these two assays use a different endpoint to assess cell viability (intracellular 
esterase activity and mitochondrial dehydrogenase, respectively). 
Calcium and sodium fluorimetry 
Increases in intracellular Ca2+ and Na+ levels were monitored as described by García-
Ratés et al. (Garcia-Ratés et al., 2010) using Ca2+-sensitive dye Fluo-4 AM (3 μM) and 
Na+-sensitive dye Corona-Green (3 μM). The fluorescence measurements were 
continued for a further 60 s or 300 s. To normalize Fluo-4 or Corona-Green signals, the 
responses from each well were calibrated by determining the maximum and minimum 
fluorescence values. This was done by adding 2 μM ionomicyn (Fmax) followed by 10 
mM EGTA (Fmin) in calcium experiments, and 1 mM gramicidin (Fmax) or tyrode 
without sodium (Fmin). Peak fluorescence responses in each well were calculated as a 
percentage of (Fmax−Fmin). The measure times were decided to determine the short-
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time effect of this substance on the cells' homeostasis (6h) and to mimic the schedule of 
in vivo treatment because kainate was administered 48h after the last dose of MDMA.  
Data analysis 
The results of the assays were compared by one-way ANOVA with Bonferroni post-hoc 
test.  All data are presented as mean ± SEM, and differences are considered significant 
at *p<0.05, **p<0.01, and ***p<0.001. The incidence of convulsions was evaluated by 
the Fisher’s exact test. To facilitate the understanding of the results, some F’s has been 
moved to the figures’legends.  
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RESULTS 
All weekly MDMA doses induced a significant increase in body temperature. Mild 
hyperthermia was apparent after MDMA 5 mg/kg (36.58 ± 0.35ºC MDMA; saline: 
36.02 ± 0.44ºC; p<0.05), MDMA 7.5 mg/kg (37.56 ± 0.39ºC MDMA; saline: 36.44 ± 
0.51ºC; p<0.001 second week; 37.91 ± 0.13ºC MDMA; saline: 36.70 ± 0.44ºC; 
p<0.0.001 third week) and 10 mg/kg (37.83 ± 0.69ºC MDMA; saline: 36.39 ± 0.52ºC; 
p<0.001). 
We investigated whether this recreational exposure could provoke a neurotoxic effect 
on neuronal terminals. In the hippocampus of animals killed 4 days post-treatment, we 
detected a non-significant decrease in the density of [3H]paroxetine binding sites, 
corresponding to serotonergic terminals (100 ± 4.8% saline, 84.33 ± 5.35% MDMA, 
p=0.10). Similarly, when assessing the dopaminergic terminal injury in striatum by 
labeling the dopamine transporter with [3H]WIN35428, we found no significant change 
in density  (100 ± 8.69% saline, 99.85 ± 8.63% MDMA, p=0.99). 
MDMA decreases seizure threshold and increased kainic acid neurotoxicity in mouse 
hippocampus 
The administration of MDMA plus KA sensitized mice to a seizure state (Table 1). We 
treated mice with saline plus KA 20 mg/kg and found that this dose convulsed only 
6.25% of the animals (1/16) with a time lag of 58 minutes and seizure intensity of 1.8 
However, previous treatment with MDMA favoured the seizure state; 64.3% mice that 
had undergone pre-treatment showed seizures (4th stage) when KA was administered 
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(9/14), the latency time was reduced by half, while seizure intensity was potentiated 
(3.6). 
As shown in Table 1, mice treated with saline plus KA 30 mg/kg showed a more severe 
convulsive state (7/8, 87.5%) with a latency of 1 hour and seizure intensity of 4.6. 
Interestingly, those mice that had previously been treated with MDMA all convulsed, 
with a latency reduced by half. However, although the mean value of intensity obtained 
was higher (5.2) it did not reach statistical significance. Only this group (M+KA30) 
experienced fatalities after KA administration (25%). 
To evaluate neurodegeneration, Fluoro-Jade B staining was performed at 24 h or 72 h 
after KA administration. No labeled cells were seen in hippocampus of saline or M 
group. In Figure 2 we show that pretreatment with MDMA significantly enhanced the 
presence of degenerating neurons due to KA 30 mg/kg in the hippocampal area CA1 at 
24 h. However, KA neurotoxicity was not modified in other hippocampal areas such as 
CA3 and the dentate gyrus (DG). Similar results were obtained 72 h post KA dosage. 
The administration of KA 20 mg/kg did not give rise to Fluoro-Jade B-positive staining, 
and MDMA pretreatment did not modify staining (data not shown). Thus, the combined 
data demonstrate that this MDMA treatment specifically potentiates KA 30 mg/kg 
neuronal toxicity, which implies the involvement of the CA1 hippocampal area.  
Glial and microglial activation in mouse hippocampus 
First we evaluated microglial activation using a specific marker of these non-neuronal 
cells, namely IBA-1. Our data demonstrated that there was mild hippocampal microglial 
activation in groups M, K20 or M+K20, which did not reach significance. In contrast, 
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mice treated with KA 30 mg/kg showed activation, which was not enhanced by the 
recreational MDMA pretreatment (F3,12= 5.809, p<0.05, see Figure 3). 
It is well known that KA favours hippocampal glial activation in rodents after an 
excitotoxic treatment. Recreational MDMA pretreatment enhances astrogliosis 
(measured using a specific antibody GFAP) in mice treated with 30 mg/kg KA (CA1: 
F3,33= 9.540, p<0.0001, DG: F3,33= 21.971 p<0.001, see Figure 4). However, given the 
lack of degenerative neurons in the hippocampus of mice treated with KA 20 mg/kg, no 
astroglial activation was observed at this dose, in either saline- or MDMA-pretreated 
animals.  
Evaluation of the calcium binding proteins:  parvalbumin, calbindin and calretinin 
CaBP afford neuroprotection by preventing the sustained increase of intracellular 
calcium. The effects of treatments on the expression of these proteins in the 
hippocampus were determined using parvalbumin, calbindin and calretinin 
immunostaining.  It is known that the immunoreactivity to these CaBP was reduced as a 
consequence of KA treatment (Junyent et al., 2011).
In our experiments, exposure to MDMA plus saline resulted in a significant reduction in 
PV-positive GABA neurons that became more apparent 72 after saline administration in 
the DG (Figures 5 and 6 and supplementary information A and B). The percentage final 
reduction by MDMA compared to control animals in this neuron type was about 68% in 
the DG and 48% in CA1. Mice treated with KA 20 mg/kg and 30 mg/kg also exhibited 
a more significant reduction in DG immunostaining than in CA1. Moreover, 
immunohistochemistry data show a decrease in this protein in the DG of mice treated 
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with the combination M+KA20 (24 h: 63.99 ± 6.47% KA20, 38.61 ± 8.76% 
M+KA20,p=0.0802; 72 h: 57.77 ± 2.48% KA20, 39.53 ± 14.26% M+KA20,p<0.05).  
With regard the protein calbindin (CB), the immunohistochemistry data at 24 h showed 
a significant decrease in this protein in the CA1 area (75.3%) and also in the DG 
granular zone (37.3%) after treatment with MDMA plus saline. This decline was also 
apparent in animals treated with KA 30 mg/kg (70.4% CA1; 70% DG)(;) Animals 
exposed to MDMA plus KA 20 mg/kg or KA 30 mg/kg did not show any enhancing 
effect versus kainate alone (Figures 5 and 6, supplementary information C). The 
parallelism between the two substances, MDMA and KA 30 mg/kg, was also evident in 
the results obtained at later times. Thus in all groups, after 72 h, calbindin levels 
exceeded and immunostaining values returned to control values  
It is well known that CR is expressed in the population of GABAergic neurons known 
as interneuron-specific cells (Gulyás et al., 1999). In our study, the density of CR-
immunostaining was significantly reduced 24 h after exposure to KA30 or MDMA, and 
this decrease was more apparent in CA1 (98.4% MDMA, 72.2% KA30) than in the DG 
(25.6% MDMA, 18.9% KA30)(Figures 5 and 6, supplementary information D)   After 
72h post kainate administration all values did not differ from saline. Animals exposed to 
MDMA plus KA 20 mg/kg or KA 30 mg/kg did not show any enhancing 
effect.However, there are also a small number of CR immunoreactive granule cells, 
mainly in the infragranular zone of the granular layer of the DG (see a supplementary 
information D). It has been reported that kainate causes the proliferation of these cells 
(Domínguez et al., 2003). Our data indicate that when animals were exposed to 
MDMA, concomitantly with the loss of CR-immunostaining in the hippocampus 
molecular layer, there was a substantial increase of it in small cells in the infragranular 
18 
zone (Saline: 100±4.61%; MDMA 48 h: 134.65±10.08%; MDMA 96 h: 133.45±8.71%, 
F=7.295, p<0.01), as also occurred in response to kainate. 
Evaluation of intracellular calcium in cortical neuronal cultures  
The entry of calcium into neurons is strongly associated with seizures (Meyer, 1989; 
McNamara, 1992) and the sustained entry induces excitotoxicity, leading to alterations 
of mitochondria and subsequent cell death (Cano-Abad et al., 2001). CaBP are crucial 
for calcium homeostasis in neurons (Baimbridge et al., 1992). When changes in CaBP 
levels are detected, this preludes fluctuations in intracellular calcium levels  
Since in vivo results demonstrate that MDMA induces changes in CaBP, the next series 
of experiments were carried out to determine whether MDMA increases cytosolic 
calcium in cultures of cortical cells or potentiates the calcium influx induced by the 
glutamatergic agonist. As KA induced a very low entry of calcium in these cultures, we 
used NMDA (N-methyl-D-aspartate), the agonist of NMDA receptors. Endogenous 
glutamate (released by activation of kainate presynaptic receptor) activates those highly 
Ca2+ permeable ionotropic receptors.  
Prior to the experiments about calcium levels, we confirmed that the MDMA 
concentrations used (10–100 µM) have no effect on cortical cell viability (calcein assay 
48 h: saline 100.00 ± 2.61%, MDMA 100 µM 107.98 ± 3.79%, n.s.; MTT assay 48 h: 
saline 100.00 ± 1.75%, MDMA 100 µM 102.92 ± 2.21%, n.s.)  
Figure 7A shows that pre-treatment of cortical neurons (6 h and 48 h) with different 
concentrations of MDMA (10–50 μM) significantly increased basal cytosolic free 
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Ca2+(F4,49=1258.7, p<0.001)). MDMA exhibited an inverse concentration- and time-
dependent effect (MDMA 10 or 50 µM higher increases at 6 h than 48 h). According to 
these results, MDMA sensitizes cortical neurons to maintain elevated intracellular levels 
of calcium and this effect is more apparent at low doses and shorter times after MDMA 
exposure. Likewise, after this pre-incubation we treated cortical neurons with 20 μM 
NMDA.  This glutamatergic agonist induced a rapid increase in fluorescence that was 
maintained for more than 5 min (results not shown). When values of calcium 
concentration were averaged out between 20–30 s after MDMA addition, we found a 
higher calcium increase when preincubation with the amphetamine derivative was 
carried out (F4,64=650.60, p<0.001) This potentiation was more apparent when using a 
short period of preincubation and low MDMA concentrations (see Figures 7B and 7C). 
In parallel with these changes in calcium homeostasis, basal levels of intracellular 
sodium were decreased (F4,64=650.60, p<0.001)48h)(Figure 8A). When a challenge of 
Kainate 500 μM were administered to the cells, the Na+ entry was higher in the cells 
pre-treated with 10 μM MDMA of both times, reaching the value of kainate alone even 
starting from lower levels (F4,45=3.281 p<0.05) (Figure 8B,C). 
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DISCUSSION 
The recreational consumption of amphetamines may be responsible for a significant 
proportion of drug-induced seizures. Thus it has been reported that MDMA induces 
seizures as a consequence of its brain neurotoxicity (Holmes et al., 1999), but other 
hypotheses have been proposed in order to explain the proconvulsant mechanism of 
MDMA. Seizures could be attributed to the metabolic effects of MDMA, mainly acute 
hyponatraemia combined with the hyperthermia that usually affects MDMA users. 
Clinical studies also suggest that the effects of MDMA modulation of the brain 
monoamine systems, specifically serotonin and norepinephine, could be responsible for 
lowering the seizure threshold. Other authors (Giorgi et al., 2006) reported the lack of 
mossy fiber sprouting at short time intervals following MDMA (2 weeks) as a possible 
explanation to this adverse effect, and recent data (Anneken and Gudelsky, 2012) lead 
to the conclusion that glutamate release could be involved in the development of 
seizures.  
Few experimental studies have analysed the last hypothesis. In the present study we 
investigated the effect of a recreational schedule of MDMA on neurotoxicity and 
seizures induced by KA. Systemic KA is a potent means of inducing limbic seizures 
with a primary action in the hippocampus between other areas (Lothman et al., 1981). 
When administered at high doses (30 mg/kg), KA can also induce neurotoxic injuries in 
the “resistant” strain C57BL/6 (Benkovic et al., 2006).  
One of the most important results of the present study is that MDMA potentiated KA 
neurotoxicity in the hippocampus and altered calcium homeostasis. These alterations 
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combined with a depletion of CaBP, markers of specific GABAergic subpopulations, 
can explain the increased susceptibility to KA-induced seizures. Our results are 
consistent with a role of MDMA in altering mouse brain excitability and unveiling 
proconvulsant activity in the presence of glutamate release. Giorgi and colleagues 
(Giorgi et al., 2005) also found evidence of this phenomenon, although they used 
different MDMA exposure. In our study, the increased susceptibility to seizures was 
specifically observed in response to low doses of KA (20 mg/kg), such that MDMA 
decreased the latency and increased the seizure intensity and the number of mice with 
seizures with respect to KA alone.   
As mentioned above, one of the most interesting results of the present study is the 
increased neuronal cell death in hippocampal neurons in area CA1 in the treatment 
group M+K30. Other hippocampal areas (the CA3 and the DG) were not affected by 
MDMA pretreatment. We also analysed microgliosis and astrogliosis as characteristics 
of KA-induced neurodegeneration. Interestingly, MDMA pretreatment, by itself, was 
not able to trigger hippocampal astro- or microgliosis. However, 30 mg/kg but not 20 
mg/kg KA induced hippocampal injury, astrogliosis and microglial activation, which is 
generally believed to contribute to neuroinflammation and neurodegeneration (Penkowa 
et al., 2001; Ravizza et al., 2005). The absence of these glial responses in MDMA 
group was reasonable, since the recreational regimen applied was not sufficient to 
produce a great degree of neuronal damage (non Fluoro-Jade B immunoreactive 
neurons, non-significant loss of serotonergic and dopaminergic terminals)(Colado et al., 
2001; O’Callaghan and Miller, 1994).  
Although the measure of the typical parameters indicatives of nerve terminal injury did 
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not show a significant effect of the applied treatment, this does not completely exclude 
minor disruptions or other consequences of MDMA exposure (Frenzilli et al., 2007). 
Such consequences probably exist as this treatment with MDMA is able to potentiate 
the astrogliosis and neurotoxic effects of KA 30 mg/kg. Anneken et al. (2013) 
concluded that, within the hippocampus, MDMA produces neuroinflammatory 
mediators and a subsequent increase in glutamate release. This assumption could 
explain the enhancement of KA-induced neurodegeneration obtained in our 
experiments.   
A large proportion of the GABAergic neurons in the hippocampal formation have been 
shown to express CaBP, thus these proteins are useful markers of specific interneuron 
subpopulations. CaBP act as intracellular facilitators of calcium diffusion or as 
intracellular calcium buffering systems. Since an increase in intracellular calcium levels 
triggers molecular events related to neuronal degeneration, it has been suggested that 
CaBP protect against calcium overload, rendering neurons more resistant to various 
toxic insults and neurodegenerative diseases (Lukas and Jones, 1994; Figueredo-
Cardenas et al., 1998; Tsuboi et al., 2000). However, the efficacy of reduced CaBPs as 
markers of neuronal death in the epileptic hippocampus has been challenged. In a study 
by Kim et al. (Kim et al., 2006) the expression of CaBPs was reduced in the 
hippocampus in a stimulus-dependent manner following electroconvulsive shock, and 
recovered to the control level later. It was concluded that the reduced expression of 
CaBPs induced by seizure activity may be indicative of the hyperactivity of CaBP-
positive neurons, which is a practical consequence of the abnormal discharge, and that 
they may play an important role in regulating seizure activity.  
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Our results demonstrated an early decrease in the expression of these different 
molecular markers when animals were exposed to high epileptogenic doses of KA, and 
we have also shown that exposure of adolescent mice to recreational doses of MDMA 
produces a similar profile of CaBPs.  
MDMA greatly reduced CB levels in CA1 hippocampus 48 h post-administration. This 
robust reduction can be attributed also to the fact that serotonergic afferents from the 
median raphe nucleus, which are affected by MDMA (Sharkey et al., 1991), were 
shown to heavily innervate CB-containing GABAergic interneurons in the hippocampus 
(Freund et al., 1990). As expected, in general, this MDMA- and KA-induced decrease 
was reversed later. Similar results were obtained in the dentate gyrus, but surprisingly, 
CB levels in groups M and M+K30 (not shown) did not return to basal values and even 
exhibited a recovery response that could be due to a rebound neuronal response leading 
to a possible process of neuroprotection (Monje et al., 2001; Yenari et al., 2001). 
CR immunoreactivity showed a similar profile to that of CB, with comparable effects in 
the K30 and MDMA groups 24 h after completing treatment.  
Additionally, both treatments increased CR immunoreactivity of granule cells in the 
infragranular zone of DG, which are considered to be recently generated neurons (Liu et 
al., 1996).  It is known that  after KA-induced hippocampal damage, the number of CR 
immunoreactive cells present in the subgranular layer increases significantly 
(Domínguez et al., 2003). These cells could represent a reservoir of pre-existing not 
completely differentiated granule cells. Surprisingly, MDMA exposure induced a 
similar intensification of this marker. This adds to the evidence of parallel effects of KA 
and the psychostimulant, which should not be surprising when one considers that this 
amphetamine derivative triggers glutamate release (Anneken and Gudelsky, 2012). 
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In the present study we also found that MDMA reduces the number of PV-positive 
neurons and that this effect is more evident at 96 h post MDMA administration. 
Moreover, KA 20 mg/kg decreases PV expression in DG, as does the combination 
MDMA+KA20. The reduction in PV interneuron activity has been reported to be 
associated with an increase in the risk of epileptogenic processes, thus increasing the 
susceptibility to seizures (Sloviter et al., 2001).  
Finally, another interesting outcome of our study is the evidence that in cultures of 
cortical neurons low concentrations of MDMA (10–50 μM) increase basal intracellular 
calcium concentrations. Our data thus suggest that previous exposure to MDMA 
sensitizes neurons to maintain high intracellular levels of calcium and potentiates the 
glutamate agonist response to an acute challenge of NMDA. These in vitro results could 
contribute to explain the observed in vivo changes in CaBP density. The reduction in 
basal intracellular sodium concentrations could also add to destabilize neuronal ionic 
homeostasis, accomplishing that Na+ entry increases, when cells are expose to kainate 
administration.. 
In conclusion, the results of the present study provide evidence that the schedule of 
MDMA used, by itself, does not induce neuronal damage but potentiates the presence of 
degenerating neurons in CA1 due to KA 30 mg/kg exposure and increases seizure 
susceptibility in all KA treatments. The MDMA-induced decrease in CaBP 
immunoreactivity, especially in the PV-positive neurons, may affect the excitability of 
hippocampal networks. The proconvulsant effect of MDMA correlates with 
modifications in these hippocampal interneurons markers and, interestingly, run in 
25 
parallel with the changes induced by KA. It can be speculated that these CaBP 
modifications could be the consequence of either a direct mechanism involving changes 
in calcium homeostasis or/and an indirect effect through glutamate release. Recently, it 
has been described that MDMA increases glutamate release in the dorsal hippocampus 
of rats (Anneken and Gudelsky, 2012), but our in vitro results point to changes in 
calcium homeostasis as an additional molecular event that can contribute also to these 
GABAergic modifications. The variation of the ionic balance observed in the cortical 
cells after the incubation with MDMA could explain that the responses to the 
depolarizing stimuli have been altered.. Probably other mechanisms such as free radical 
production or the modification on mossy fiber sprouting could also promote this 
convulsive susceptibility.  
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Legends for figures: 
FIGURE 1: Treatment schedule. Animals were randomly assigned to the following 
treatment groups: saline+saline, MDMA+saline (M), saline+kainate 20 mg/kg (KA20), 
MDMA+kainate 20 mg/kg (M+KA20), saline+kainate 30 mg/kg (KA30), 
MDMA+kainate 30 mg/kg (M+KA30). The animals (n=7–10  for each treatment group 
in each experiment) received a chronic dosage regimen of saline (5 ml/kg) or MDMA 
t.i.d. (s.c, every 3 h) on 1 day a week, for 4 consecutive weeks. On the day of treatment, 
the environmental temperature was 26±1 °C and this was maintained until 2 h after the 
last dose. Twenty-four hours after the last dose of MDMA or saline, animals were 
exposed to KA i.p. 20 or 30 mg/kg. Latency and presence of seizures were recorded 
immediately after KA administration and the animals were killed 24 h or 72 h later.  
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FIGURE 2:  Pretreatment with MDMA significantly enhanced the presence of 
degenerating neurons due to KA 30 mg/kg in hippocampal area CA1. Panel A and B 
show the number of Fluoro-Jade-positive neurons, in different hippocampal areas (CA1, 
CA3 and DG), 24 h and 72 h post KA30 mg/kg administration, respectively. C: 
Representative horizontal sections of hippocampal subfield CA1 (C1–C2 24 h and C3–
C4 72 h post KA administration). *p<0.05 versus KA30 in the same area. 
FIGURE 3: 24 h post KA administration mice were killed for histological analysis of 
microgliosis using Iba-1. Representative immunohistochemistry for Iba-1 expression in 
horizontal sections of hippocampus from animals treated with saline+saline (A,B) 
MDMA+saline (C,D), saline+KA 30 mg/kg (E,F) or MDMA+KA 30 mg/kg (G,H). 
Scale bars: 200 μm in the upper panels, 20 μm in the lower panels. Recreational MDMA 
pretreatment did not enhance the effect of KA. 
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FIGURE 4: 3 days post KA administration mice were killed for histological analysis of 
astrogliosis using GFAP. Upper panel shows the quantification of GFAP 
immunostaining density in CA1 and DG areas of hippocampus. *p<0.05 and *** 
p<0.001 versus saline; ## p<0.01 versus K30 in the same area. Lower panels show 
representative immunohistochemistry for GFAP expression in horizontal sections of 
hippocampus from animals treated with saline+saline (A,B) MDMA+saline (C,D), 
saline+KA 30 mg/kg (E,F) or MDMA+KA 30 mg/kg (G,H). Scale bars: 200 μm in the 
upper panels, 20 μm in the lower panels. Recreational MDMA pretreatment enhanced 
KA-induced astrogliosis. 
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FIGURE 5: Effect of treatment on hippocampal parvalbumin (A,B), calbindin (C,D) 
and calretinin (E,F) immunoreactivity in CA1 of mouse groups: saline+KA 20 mg/kg 
(K20), saline+KA 30 mg/kg (K30) and MDMA+saline (MDMA), Left panel: 
kainate effects; (F4,16=3.259 p<0.05 PV; F4,30=15.906 p<0.0010.001 CB; F4,41=24.584 
p<0.001 CR) right panel: MDMA effects (F2,17=3.964 p<0.05 PV; F2,18=17.608 p<0.001 
CB; F2,24=43.982 p<0.001). Temporal bars under figures display the 
time elapsed between the last kainate or saline administration and sacrifice ; . *p<0.05; 
**p<0.01and ***p<0.001 versus. saline.  
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FIGURE 6: Effect of treatment on hippocampal parvalbumin (A,B), calbindin (C,D) 
and calretinin (E,F) immunoreactivity in dentate gyrus of mouse groups: saline+KA 20 
mg/kg (K20), saline+KA 30 mg/kg (K30), MDMA+saline (MDMA).Left panel: kainate 
effects (F4,16=6.588 p<0.05 PV; F4,32=21.077 p<0.001 CB; F4,48=5.418 p<0.01 CR); 
right panel: MDMA effects (F2,17=13.91 p<0.001 PV; F2.17=13.475 p<0.001 CB; 
F2.29=13.158 p<0.001 CR). Temporal bars under figures display the 
time elapsed between the last kainate or saline administration and sacrifice . *p<0.05; 
**p<0.01  and ***p<0.001 versus. saline.  
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FIGURE 7: Assays in cultured cortical cells. Effect of 6 h or 48 h preincubation with 
MDMA 10 (M10) or 50 µM (M50) on intracellular calcium levels. Panel A: basal 
intracellular calcium levels.. Panel B:time-course of the increases in Fluo-4 fluorescence 
after the addition of NDMA 20 µM (at the arrow), in cells pre-treated for 6 h with saline 
or MDMA 10 or 50 µM. Panel C: increase in cytosolic calcium induced by NDMA 20 
µM (values of Fluo-4 were averaged between 20–30 s after MDMA addition).. *** 
p<0.001 versus saline; ### p<0.001 versus time-matched MDMA 50 µM.  
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FIGURE 8: Assays in cultured cortical cells. Effect of 6 h or 48 h preincubation with 
MDMA 10 (M10) or 50 µM (M50) on intracellular sodium levels. Panel A: basal 
intracellular sodium levels Panel B: time-course of the increases in Corona-Green 
fluorescence after the addition of Kainate  500µM (at the arrow), in cells pre-treated for 
6 h with saline or MDMA 10 or 50 µM. Panel C:  sodium entry values/entry after 
kainate administration. *p<0.05; *** p<0.001 versus saline; ## p<0.01 and ### 
p<0.001 versus time-matched MDMA 50 µM.  
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Table 1. Effects of treatment on motor seizures measured as number of animals with tonic–clonic convulsions, time delay to show them 
immediately after KA administration and seizure intensity (according to scale of severity explained in materials and methods 
$ n/N: Number of animals that showed seizure episodes (4th stage)/number of animals per group. ***p<0.001 versus the corresponding kainate 
group. 
Treatment group 
Animals with 
seizures n/N$ 
Latency (min) Seizure intensity Mortality 
MDMA+saline (M) 0/8 0 0 0/8 
Saline+Kainate  20 mg/kg (KA20) 1/16 58.00 1.8 ± 0.2 0/16 
MDMA+Kainate 20 mg/kg (M+KA20) 9/14*** 30.00 ± 4.87*** 3.6 ± 0.2*** 0/14 
Saline+Kainate 30 mg/kg (KA30) 7/8 51.14 ± 6.36 4.6 ± 0.3 0/8 
MDMA+Kainate 30 mg/kg (M+KA30) 8/8 24.37 ± 7.52*** 5.2 ± 0.3 2/8 
